A Comprehensive Monograph on Dopamine (DB00988): Pharmacology, Clinical Utility, and Safety Profile

Executive Summary

Dopamine, an endogenous catecholamine, holds a dual identity of profound significance in medicine: it is both an essential neurotransmitter that governs fundamental brain functions and a potent, intravenously administered sympathomimetic agent indispensable in critical care. As a neurotransmitter, its discovery and the elucidation of its role in motor control and reward pathways revolutionized neuroscience and led to breakthrough treatments for conditions like Parkinson's disease. As a pharmaceutical agent, identified by DrugBank ID DB00988 and CAS Number 51-61-6, it is a cornerstone therapy for the management of severe hemodynamic instability.

The pharmacological profile of intravenous dopamine is distinguished by a unique dose-dependent mechanism of action. At low infusion rates, it primarily stimulates dopaminergic receptors, promoting renal and mesenteric vasodilation. At intermediate rates, it exerts positive inotropic and chronotropic effects through beta-1 adrenergic receptor stimulation, enhancing cardiac output. At high rates, it acts on alpha-1 adrenergic receptors, causing systemic vasoconstriction to increase blood pressure. This therapeutic versatility allows clinicians to titrate the drug to achieve specific physiological goals in the management of shock syndromes arising from diverse etiologies such as myocardial infarction, septicemia, and major surgery.

Despite its utility, dopamine possesses a narrow therapeutic index and a significant risk profile. Its administration is confined to high-acuity settings where continuous monitoring of cardiovascular and renal parameters is possible. Key safety concerns include the potential for cardiac arrhythmias, excessive vasoconstriction leading to peripheral ischemia, and severe tissue necrosis upon extravasation from the infusion site. Consequently, its safe and effective use is predicated on a deep understanding of its complex pharmacology and strict adherence to established protocols for administration, titration, and patient monitoring. This monograph provides an exhaustive analysis of dopamine, synthesizing information on its chemical properties, historical context, detailed pharmacology, clinical applications, and comprehensive safety profile to serve as an authoritative reference for clinicians and researchers.

Section 1: Foundational Profile of Dopamine

This section establishes the fundamental identity of dopamine, covering its precise chemical makeup and the pivotal historical context of its discovery. This foundation is crucial for appreciating its dual role as a natural physiological modulator and a powerful pharmacological agent.

1.1 Chemical Identity and Physicochemical Properties

Dopamine is a small molecule classified as a catecholamine, a group of monoamines that share a distinct catechol nucleus—a benzene ring with two adjacent hydroxyl (OH) groups—and an amine side chain.[1] Endogenously, it is derived from the amino acid tyrosine and serves as a precursor to the other major catecholamines, norepinephrine and epinephrine.[1]

Chemical Structure and Nomenclature

The formal chemical structure of dopamine is a catechol group where the hydrogen at position 4 is substituted by a 2-aminoethyl group.2 This structure is the basis for its interactions with a wide range of dopaminergic and adrenergic receptors. Its official International Union of Pure and Applied Chemistry (IUPAC) name is 4-(2-aminoethyl)benzene-1,2-diol.2 The molecule is represented by the chemical formula

C8​H11​NO2​ and has a molecular weight of approximately 153.18 g/mol.[3]

Due to its long history and widespread study, dopamine is known by numerous synonyms, including 3-Hydroxytyramine, 4-(2-Aminoethyl)pyrocatechol, 3,4-Dihydroxyphenylethylamine, Oxytyramine, and Intropin.[2] To ensure unambiguous identification across scientific and regulatory domains, it is cataloged with a variety of unique identifiers, which are consolidated in Table 1.

Physicochemical Properties

In its pure form, dopamine is a solid that can appear as stout prisms or a white to off-white crystalline powder.2 It is highly soluble in water (60.0 g/100 ml) and also soluble in alcohol.3 The melting point is consistently reported as 128 °C.2

The chemical structure that defines its biological activity also dictates its pharmaceutical limitations. The catechol and amine functional groups are essential for binding to its target receptors, but they also render the molecule chemically unstable and highly susceptible to oxidation. This instability is particularly pronounced in alkaline environments, which is why pharmaceutical preparations are formulated as the hydrochloride salt (dopamine HCl) to enhance stability and water solubility.[10] This inherent chemical property is the direct reason for its clinical incompatibility with alkaline solutions such as sodium bicarbonate, as contact leads to rapid inactivation of the drug.[7] The molecule is also sensitive to iron salts and other oxidizing agents, necessitating specific handling and storage precautions.[7]

Table 1: Key Chemical and Physical Identifiers for Dopamine

Identifier Type	Value	Source(s)
Systematic & Common Names
IUPAC Name	4-(2-aminoethyl)benzene-1,2-diol	2
Common Name	Dopamine	1
Synonyms	3-Hydroxytyramine; 4-(2-Aminoethyl)pyrocatechol	2
Formula & Weight
Chemical Formula	C8​H11​NO2​	2
Molecular Weight	153.18 g/mol	3
Registry Numbers
CAS Number	51-61-6	2
DrugBank ID	DB00988	1
PubChem CID	681	2
ChEBI ID	CHEBI:18243	2
UNII	VTD58H1Z2X	2
EC Number	200-110-0	2
RXCUI	3628	2
Structural Identifiers
SMILES	C1=CC(=C(C=C1CCN)O)O	2
InChIKey	VYFYYTLLBUKUHU-UHFFFAOYSA-N	2

1.2 Historical Perspective: From Precursor to Nobel-Winning Neurotransmitter

The journey of dopamine from a chemical curiosity to a central figure in neuroscience is a quintessential narrative of scientific discovery and translational medicine. Its story begins not with a breakthrough, but with a series of early observations that failed to grasp its significance. The precursor molecule, L-Dopa, was first synthesized by Casmir Funk in 1911.[5] In 1913, Marcus Guggenheim isolated L-Dopa from bean seedlings and, after ingesting a 2.5-gram dose, experienced severe nausea and vomiting. Observing no other significant effects in himself or in animals, he concluded the substance was biologically inert, a misconception that would delay its study for decades.[5]

The paradigm shifted dramatically in the late 1950s through the groundbreaking work of the Swedish pharmacologist Arvid Carlsson. At the time, dopamine was widely regarded as nothing more than a metabolic intermediate in the synthesis of norepinephrine.[13] In a series of elegant experiments beginning in 1957, Carlsson demonstrated that dopamine was, in fact, an independent and abundant neurotransmitter within the central nervous system.[13] His key experiment involved administering the drug reserpine to animals, which was known to deplete monoamines. This induced a state of akinesia, a profound loss of motor control strikingly similar to the symptoms of Parkinson's disease.[13] Carlsson then showed that administering the precursor L-DOPA reversed this motor deficit. Crucially, he correlated this functional recovery with the restoration of dopamine levels in the brain, while levels of norepinephrine remained depleted.[13] This finding definitively proved that dopamine itself, not norepinephrine, was essential for the regulation of movement. For this discovery, which laid the foundation for modern neuropharmacology, Carlsson was awarded the Nobel Prize in Physiology or Medicine in 2000.[13]

Carlsson's functional discovery was quickly followed by critical anatomical evidence. His students, along with researchers in Japan, found that dopamine was not uniformly distributed in the brain but was highly concentrated in the striatum (a key component of the basal ganglia), a region known to be involved in motor control.[13] This anatomical specificity provided the crucial link between the chemical and its function. This progression from basic science to pathophysiology was completed when Oleh Hornykiewicz and Herbert Ehringer, inspired by these findings, analyzed the brains of deceased Parkinson's disease patients. They discovered a severe and consistent depletion of dopamine in the very same striatal regions.[13]

This direct link between a specific neurochemical deficiency and a major neurological disease was a landmark achievement in medicine. It immediately suggested a logical therapeutic strategy: dopamine replacement. This led to the first clinical trials of L-DOPA in Parkinson's patients. The major therapeutic breakthrough came in 1967, when George Cotzias developed the high-dose oral L-DOPA regimen that remains the gold standard of treatment today.[13] The success of L-DOPA therapy triggered an explosion of interest in dopamine, with the number of related scientific publications increasing tenfold in the following decade.[13] This historical arc—from a fundamental biochemical discovery to a deep understanding of disease pathology and culminating in a revolutionary clinical therapy—stands as a powerful testament to the process of translational medicine.

Section 2: Comprehensive Pharmacology

This section deconstructs the complex pharmacological profile of dopamine, explaining its endogenous synthesis and metabolism, its unique dose-dependent interactions with multiple receptor systems, the distinction between its central and peripheral effects, and the pharmacokinetic properties that dictate its clinical administration.

2.1 Biosynthesis and Metabolism

The pharmacological actions of dopamine are rooted in its natural lifecycle within the body, from its synthesis in specialized cells to its rapid enzymatic degradation.

Endogenous Synthesis

Dopamine is produced naturally in a restricted set of cells, most notably in dopaminergic neurons of the brain (such as those in the substantia nigra and ventral tegmental area) and in the chromaffin cells of the adrenal medulla.5 The primary biosynthetic pathway begins with the essential amino acid L-phenylalanine, which is converted to L-tyrosine. The main pathway then proceeds via two enzymatic steps 10:

1. L-Tyrosine to L-DOPA: The amino acid L-tyrosine is hydroxylated to form 3,4-dihydroxyphenylalanine (L-DOPA). This reaction is catalyzed by the enzyme tyrosine hydroxylase (TH) and requires oxygen, iron (Fe2+), and tetrahydrobiopterin (BH4) as cofactors. This is the rate-limiting step in the synthesis of all catecholamines, making TH a key point of regulation.[19]
2. L-DOPA to Dopamine: L-DOPA undergoes decarboxylation (removal of a carboxyl group) to form dopamine. This reaction is catalyzed by the enzyme aromatic L-amino acid decarboxylase (AADC), also known as DOPA decarboxylase, which uses pyridoxal phosphate as a cofactor.[1]

Once synthesized in the neuron's cytoplasm, dopamine is actively transported into synaptic vesicles by the vesicular monoamine transporter 2 (VMAT2). This packaging protects it from enzymatic degradation within the neuron and prepares it for release into the synaptic cleft upon neuronal firing.[17]

Metabolism and Elimination

Dopamine's action, whether as a neurotransmitter or an administered drug, is terminated by its rapid removal and breakdown. This is accomplished through reuptake into the presynaptic neuron via the dopamine transporter (DAT) and enzymatic degradation by two key enzymes 17:

• Monoamine Oxidase (MAO): This enzyme, which exists in two isoforms (MAO-A and MAO-B), is found on the outer membrane of mitochondria within neurons and glial cells. MAO oxidizes dopamine to 3,4-dihydroxyphenylacetaldehyde (DOPAL), which is then rapidly converted by aldehyde dehydrogenase to the inactive metabolite 3,4-dihydroxyphenylacetic acid (DOPAC).[17]
• Catechol-O-methyltransferase (COMT): This enzyme is primarily located extraneuronally, including in glial cells and the liver and kidneys. COMT transfers a methyl group to the 3-hydroxyl position of the catechol ring, converting dopamine to 3-methoxytyramine (3-MT).[17]

The two major final inactive metabolites are produced through the sequential action of these enzymes. The primary excretion products found in urine are homovanillic acid (HVA), which is formed when either DOPAC is methylated by COMT or 3-MT is oxidized by MAO, and DOPAC itself.[1] Following intravenous administration, dopamine is rapidly metabolized in the liver, kidney, and plasma. Approximately 80% of the drug is excreted in the urine within 24 hours, predominantly as HVA and DOPAC and their sulfate and glucuronide conjugates, with a very small portion excreted unchanged.[1]

The central role of these metabolic enzymes in dopamine clearance has profound clinical implications. The enzymatic breakdown by MAO is the direct reason for the most severe drug-drug interaction associated with dopamine. When patients are treated with MAO inhibitors (MAOIs), this primary clearance pathway is blocked, leading to a massive accumulation of dopamine and an exaggerated, often dangerous, pharmacological response. This mechanistic understanding is the basis for the clinical guideline that requires a 90% reduction in the initial dopamine dose for patients recently treated with MAOIs.[23]

2.2 Mechanism of Action: A Dose-Dependent Receptor Profile

The therapeutic utility and flexibility of intravenous dopamine stem from its complex and unique mechanism of action, which is characterized by dose-dependent engagement of different receptor subtypes. Dopamine acts as a direct agonist at its own family of five G-protein coupled receptors (D1-D5) and also at alpha- and beta-adrenoceptors.[1] The predominant physiological effect observed clinically is a direct function of the infusion rate, allowing the drug to be titrated to achieve distinct therapeutic goals. This pharmacological spectrum is detailed in Table 2.

Receptor Targets and Dose-Related Effects

• Low Dose (Renal/Dopaminergic Range: 0.5–2 mcg/kg/min): At low infusion rates, dopamine's effects are primarily mediated by its agonism at dopamine D1 receptors. These receptors are abundant in the vascular beds of the kidneys, mesentery, heart, and brain.[19] Stimulation of D1 receptors on vascular smooth muscle leads to vasodilation, which in the renal vasculature results in increased renal blood flow, glomerular filtration rate, and sodium excretion, thereby increasing urine output.[19] This effect was historically referred to as the "renal dose" of dopamine, though its ability to confer a protective effect on the kidneys or improve overall patient outcomes has been a subject of debate, with some evidence suggesting it does not improve renal function when used for this purpose alone.[26]
• Intermediate Dose (Inotropic/Beta-Adrenergic Range: 2–10 mcg/kg/min): As the infusion rate increases, dopamine begins to exert significant effects on the heart by stimulating beta-1 adrenoceptors in the myocardium.[20] This results in a positive inotropic effect (increased myocardial contractility) and a positive chronotropic effect (increased heart rate), which together lead to a substantial increase in cardiac output.[1] This action is beneficial in states of low cardiac output, such as cardiogenic shock and congestive heart failure. Dopamine also indirectly contributes to this effect by causing the release of endogenous norepinephrine from sympathetic nerve endings.[1] At this dose range, there is little to no stimulation of beta-2 adrenoceptors, so peripheral vasodilation is not a prominent feature.[7]
• High Dose (Vasopressor/Alpha-Adrenergic Range: >10 mcg/kg/min): At higher infusion rates, typically exceeding 10 mcg/kg/min and becoming more prominent above 20 mcg/kg/min, the effects of dopamine are dominated by the stimulation of alpha-1 adrenoceptors on vascular smooth muscle.[20] This alpha-1 agonism causes potent systemic vasoconstriction, leading to an increase in systemic vascular resistance (SVR) and a corresponding rise in arterial blood pressure.[23] This vasopressor effect is the primary rationale for its use in patients with profound hypotension and distributive shock.

This dose-dependent spectrum is both the greatest asset and the most significant challenge of dopamine therapy. It provides clinicians with a single agent that can be titrated to provide renal, cardiac, or vasopressor support. However, this also means that the drug's fundamental mechanism of action changes as the dose is adjusted in response to a patient's evolving clinical status. For instance, a dose increase intended to augment blood pressure (an alpha-mediated effect) may inadvertently precipitate dangerous tachyarrhythmias (a beta-mediated effect) or compromise peripheral circulation through excessive vasoconstriction. Safe and effective use, therefore, requires a continuous and nuanced understanding of this shifting pharmacological profile.

Table 2: Dose-Dependent Receptor Activity and Clinical Effects of Intravenous Dopamine

Dose Range (mcg/kg/min)	Primary Receptor(s) Activated	Primary Physiological Effect	Primary Therapeutic Goal	Source(s)
Low (0.5–2)	Dopamine D1	Vasodilation (renal, mesenteric, coronary)	Increase renal blood flow and urine output	19
Intermediate (2–10)	Beta-1 Adrenergic	Positive Inotropy (↑ contractility) Positive Chronotropy (↑ heart rate)	Increase cardiac output	20
High (>10)	Alpha-1 Adrenergic	Systemic Vasoconstriction (↑ SVR)	Increase systemic blood pressure	20

2.3 Pharmacodynamics: Central and Peripheral Effects

Dopamine exhibits two distinct pharmacological identities, which are physically and functionally separated by the blood-brain barrier. Its role as an endogenous neurotransmitter in the central nervous system (CNS) is fundamentally different from its function as an exogenously administered drug acting on the periphery.

Central Nervous System (CNS) Role

Within the brain, dopamine is a master regulator of numerous critical functions, operating through several distinct neuronal pathways 1:

• Motor Control: The nigrostriatal pathway, which projects from the substantia nigra to the striatum, is paramount for the initiation and smooth execution of voluntary movement. The profound loss of dopaminergic neurons in this pathway is the defining pathological hallmark of Parkinson's disease, leading to symptoms of bradykinesia, rigidity, and tremor.[6]
• Reward, Motivation, and Addiction: The mesolimbic pathway, originating in the ventral tegmental area (VTA) and projecting to limbic structures like the nucleus accumbens, is the brain's primary reward circuit. It mediates feelings of pleasure and reinforcement, driving reward-motivated behaviors. The dysregulation of this pathway is central to the pathophysiology of substance use disorders, as many addictive drugs act by artificially increasing dopamine release in this circuit.[6] Overactivity in this pathway is also implicated in the positive symptoms (e.g., hallucinations, delusions) of schizophrenia.[22]
• Cognition and Executive Function: The mesocortical pathway, which also originates in the VTA but projects to the prefrontal cortex, is crucial for higher-order cognitive functions, including attention, working memory, and complex planning.[19]

Peripheral (Pharmacological) Effects

When administered intravenously as a medication, dopamine cannot cross the blood-brain barrier to a significant extent.10 Therefore, its therapeutic effects are confined to peripheral systems. This physical barrier is the single most important factor separating the clinical use of dopamine in critical care from the neurology and psychiatry of central dopaminergic systems. It explains why a patient in an intensive care unit receiving a high-dose dopamine infusion does not experience the psychoactive or motor effects associated with central dopamine modulation. Conversely, it is the reason why the precursor L-DOPA, which can cross the blood-brain barrier, is used to treat Parkinson's disease instead of dopamine itself.

The peripheral effects of administered dopamine are mediated by its actions on dopaminergic and adrenergic receptors outside the CNS:

• Cardiovascular System: As detailed previously, dopamine exerts powerful effects on the heart and blood vessels. It produces positive chronotropic and inotropic effects via beta-1 receptor stimulation and indirectly by promoting norepinephrine release, and it causes vasoconstriction via alpha-1 receptor stimulation.[1]
• Renal System: Stimulation of D1 receptors in the renal vasculature causes vasodilation, which can lead to an increase in renal blood flow and urine output.[5]
• Endocrine System: Peripherally, dopamine is the immediate precursor in the synthesis of norepinephrine and epinephrine in the adrenal medulla and sympathetic nerve terminals.[1]

2.4 Pharmacokinetics: Administration, Distribution, and Elimination

The pharmacokinetic profile of dopamine—its absorption, distribution, metabolism, and excretion (ADME)—is characterized by rapid action and rapid clearance, properties that define its clinical role as a titratable, short-acting agent for acute conditions.

Administration and Onset

Dopamine cannot be administered orally, as it is rapidly metabolized in the gastrointestinal tract and liver and would not reach systemic circulation. Therefore, it must be administered as a continuous intravenous infusion.19 This method allows for precise control over the plasma concentration and therapeutic effect. The onset of action is very rapid, occurring within five minutes of initiating the infusion.7

Distribution

Following intravenous administration, dopamine is widely distributed throughout the body's peripheral tissues. However, as previously noted, its polarity and size prevent it from crossing the blood-brain barrier in significant amounts, confining its actions to the periphery.10 There is currently no information available on its protein binding in plasma.1

Half-Life and Duration of Action

Dopamine has an extremely short plasma half-life, estimated to be between 1 and 2 minutes in adults.10 This rapid clearance is due to efficient uptake by cells and swift enzymatic metabolism. Consequently, its duration of action is also very short, lasting less than ten minutes after the infusion is stopped.7 This pharmacokinetic profile is ideal for the critical care setting. The rapid onset allows for immediate hemodynamic support, while the short half-life provides a crucial safety feature: if a serious adverse effect such as a life-threatening arrhythmia or severe hypertension occurs, it can be quickly reversed by simply discontinuing the infusion. This "on/off" controllability is essential when managing hemodynamically volatile patients. The only exception to this rapid clearance is in the presence of MAO inhibitors, which can block its primary metabolic pathway and prolong its duration of action to as long as one hour.7

Metabolism and Elimination

As described in Section 2.1, dopamine is extensively and rapidly metabolized in the liver, kidneys, and plasma by the enzymes MAO and COMT. The resulting inactive metabolites, primarily HVA and DOPAC, are then excreted by the kidneys into the urine.1

Section 3: Clinical Application in Critical Care

This section translates the foundational and pharmacological principles of dopamine into its practical application in the clinical setting. It details the approved indications, specific protocols for dosage and administration, and important considerations for use in special patient populations.

3.1 Approved Indications and Therapeutic Rationale

Intravenous dopamine is a cornerstone of therapy for the management of acute hemodynamic instability. Its primary FDA-approved indication is for the correction of hemodynamic imbalances present in the shock syndrome, regardless of the underlying etiology.[1] Shock is a physiological state characterized by systemic hypoperfusion, leading to inadequate oxygen delivery to tissues. Dopamine's utility lies in its ability to provide temporary physiological support to the failing components of the cardiovascular system—namely, cardiac contractility and vascular tone—thereby restoring perfusion and buying critical time for clinicians to diagnose and treat the root cause of the shock. It is a supportive therapy, not a curative one.

The specific conditions leading to shock where dopamine is indicated include:

• Cardiogenic Shock: Following myocardial infarction or in cases of chronic cardiac decompensation (e.g., congestive heart failure), where the heart's pumping function is severely impaired.[1]
• Septic Shock: Resulting from endotoxic septicemia, where systemic inflammation leads to profound vasodilation and myocardial depression.[1]
• Traumatic Shock: Arising from severe physical trauma.[1]
• Post-Surgical States: Following major procedures such as open-heart surgery.[1]
• Renal Failure: Where associated with hemodynamic collapse.[1]

Within this broad indication, dopamine is used to achieve specific therapeutic goals:

• Management of Hypotension: To treat low blood pressure, dopamine is titrated to its moderate-dose (beta-adrenergic) range to increase cardiac output or to its high-dose (alpha-adrenergic) range to increase systemic vascular resistance.[1]
• Treatment of Bradycardia: The positive chronotropic effects mediated by beta-1 receptor stimulation can be used to increase a pathologically slow heart rate.[20]
• Support of Low Cardiac Output: The positive inotropic effects are used to strengthen myocardial contractions and improve the heart's pumping efficiency.[1]

A critical prerequisite for the initiation of dopamine therapy is the correction of hypovolemia. Administering a vasopressor to a patient with an inadequate circulating volume can lead to severe peripheral and visceral vasoconstriction, further compromising tissue perfusion despite a seemingly "normal" blood pressure reading. Therefore, blood volume should be restored with appropriate fluids, such as whole blood or plasma expanders, before starting a dopamine infusion.[9]

3.2 Dosage, Administration, and Monitoring Protocols

The potent effects and narrow therapeutic index of dopamine necessitate meticulous and protocol-driven administration, which is exclusively performed in a high-acuity environment like an intensive care unit (ICU).

Dosage and Titration

Dopamine dosage is calculated based on patient weight and administered in micrograms per kilogram per minute (mcg/kg/min). The infusion must be individually titrated to achieve the desired hemodynamic and/or renal response, with constant re-evaluation of the patient's condition.8

• Starting Dose: Infusion is typically initiated at a rate of 2–5 mcg/kg/min.
• Titration: The dose is gradually increased in increments of 5–10 mcg/kg/min at intervals, up to a rate of 20–50 mcg/kg/min, as needed to achieve the therapeutic target (e.g., mean arterial pressure, cardiac output, urine output).[8] Doses exceeding 50 mcg/kg/min have been used in advanced circulatory failure but are associated with a higher risk of adverse effects.
• Weaning: Due to the risk of rebound hypotension, the dopamine infusion must not be stopped abruptly. The dose should be gradually tapered down while concurrently expanding the patient's intravascular volume with intravenous fluids to ensure a smooth transition off vasopressor support.[12]

Administration

• Route of Administration: Dopamine is administered exclusively as a continuous intravenous infusion using a calibrated infusion pump to ensure precise and consistent delivery.[20] Bolus administration must be strictly avoided.[23]
• Intravenous Access: Due to the severe risk of tissue necrosis from extravasation, a central venous catheter (CVC) is the preferred route of administration. If a CVC is not immediately available in an emergency, a large, stable peripheral vein, such as in the antecubital fossa, may be used temporarily. The infusion site must be continuously monitored for signs of infiltration (e.g., pain, swelling, blanching), and a central line should be placed as soon as feasible.[9]
• Solution Preparation: Dopamine hydrochloride is diluted in a compatible intravenous fluid, such as 5% Dextrose in Water (D5W), 0.9% Sodium Chloride (Normal Saline), or Ringer's Lactate.[26] The solution should be visually inspected before use; any solution that appears yellow, brown, or otherwise discolored has likely undergone oxidation, lost potency, and must be discarded.[26]

Essential Monitoring

The use of dopamine mandates intensive and continuous patient monitoring to guide titration and detect adverse effects promptly. The level of monitoring required effectively restricts its use to an ICU setting, which has significant implications for patient placement and healthcare resource allocation.

• Cardiovascular Monitoring: Continuous electrocardiogram (ECG) monitoring is mandatory to detect arrhythmias. Blood pressure must be monitored frequently, preferably via an indwelling arterial catheter for continuous, real-time measurement, especially for patients on higher doses or prolonged infusions.[12]
• Renal Monitoring: Urine output should be measured hourly as a key indicator of renal perfusion and overall organ function.[8]
• Perfusion Monitoring: The patient's peripheral circulation must be assessed regularly, monitoring for changes in skin color, temperature, and capillary refill in the extremities to detect signs of excessive vasoconstriction and ischemia.[12]

3.3 Special Populations

The use of dopamine in certain patient populations requires additional caution and specific considerations due to altered pharmacokinetics or increased susceptibility to adverse effects.

Pediatric Use

The safety and effectiveness of dopamine in pediatric patients, particularly neonates, have not been fully established, and robust evidence to define optimal dosing is lacking.7 The clearance of dopamine is highly variable in children and can be up to twice as fast in those under two years of age. Neonates may be particularly sensitive to the vasoconstrictive effects of the drug.23 Therefore, therapy should be initiated at a low starting dose (e.g., 1–5 mcg/kg/min) with very slow and cautious titration based on the patient's hemodynamic response. There have also been reports of vasospastic events when dopamine was infused through umbilical artery catheters, warranting caution with this route of administration.23

Geriatric Use

While clinical studies have not identified consistent differences in response between older and younger patients, general principles of geriatric pharmacology apply. Dose selection for elderly patients should be cautious, typically starting at the low end of the dosing range. This approach accounts for the higher prevalence of co-morbidities and the greater likelihood of decreased hepatic, renal, or cardiac function in this population, which can alter drug clearance and increase the risk of adverse effects.23

Pregnancy and Lactation

Dopamine is classified as Pregnancy Category C. Animal reproduction studies have not demonstrated a risk of teratogenicity, but there are no adequate and well-controlled studies in pregnant women. It is unknown if dopamine crosses the placental barrier. Therefore, it should be used during pregnancy only if the potential benefit to the mother clearly justifies the potential risk to the fetus.7 It is also not known whether dopamine is excreted in human milk, so caution should be exercised when administering it to a nursing mother.7

Section 4: Safety, Risk Management, and Interactions

This section provides a comprehensive overview of the risks associated with dopamine therapy. It includes a systematic review of its adverse effects, a detailed discussion of critical warnings and contraindications, and an analysis of clinically significant drug-drug interactions.

4.1 Adverse Effects Profile

Dopamine is a potent vasoactive agent with a significant potential for adverse effects, which are often extensions of its pharmacological actions. The frequency and severity of these effects are typically dose-dependent.

Cardiovascular System

The most common and clinically significant adverse reactions involve the cardiovascular system:

• Arrhythmias: Due to its beta-1 adrenergic stimulation, dopamine frequently causes cardiac rhythm disturbances. These can range from relatively benign ectopic beats and sinus tachycardia to more serious arrhythmias such as atrial fibrillation and ventricular arrhythmias. Fatal ventricular arrhythmias have been reported, particularly at very high doses.[1]
• Hemodynamic Effects: Hypertension is a common effect at higher, alpha-adrenergic doses. Paradoxically, hypotension can also occur. Palpitations and anginal pain may be experienced due to increased myocardial oxygen demand.[1]
• Peripheral Vasoconstriction and Ischemia: The alpha-adrenergic effects can lead to excessive vasoconstriction, resulting in cold extremities, peripheral cyanosis, and, in severe cases, gangrene. This risk is particularly elevated in patients with pre-existing occlusive vascular disease and with prolonged high-dose infusions.[12]

Local Infusion Site Reactions

• Extravasation and Tissue Necrosis: Leakage of dopamine from the vein into the surrounding subcutaneous tissue (extravasation) is a serious complication. The drug's potent local vasoconstrictive properties can lead to severe tissue ischemia, resulting in necrosis (tissue death) and sloughing.[33] This is the primary reason why administration through a central venous line is strongly preferred.

Other Organ Systems

• Gastrointestinal: Nausea and vomiting are common adverse effects.[1]
• Central Nervous System: Headache and anxiety are frequently reported.[23]
• Respiratory: Dyspnea (shortness of breath) can occur.[23]
• Renal: Azotemia, an elevation of nitrogenous waste products (like urea) in the blood, has been reported.[23]
• Dermatologic: Piloerection (goosebumps) may be observed.[23]

4.2 Warnings, Precautions, and Contraindications

The safe use of dopamine is contingent upon strict adherence to several critical warnings and precautions issued by regulatory agencies.

Key Warnings

• Tissue Ischemia and Extravasation: This is arguably the most significant warning associated with dopamine administration. To mitigate the risk of extravasation, the drug should be infused into a large vein or, preferably, a central line, and the infusion site must be checked frequently for free flow.[9] In the event that extravasation occurs, immediate intervention is required to prevent tissue necrosis. This provides a clear example of mechanism-based toxicology management: the adverse event (ischemia) is caused by intense local alpha-1 receptor stimulation, and the antidote works by directly blocking this action. The established emergency treatment is to infiltrate the ischemic area as soon as possible with 5 to 10 mg of phentolamine mesylate (an alpha-adrenergic blocking agent) diluted in 10 to 15 mL of normal saline. This sympathetic blockade causes immediate local vasodilation and restores blood flow if administered within 12 hours of the event.[23]
• Cardiac Arrhythmias: Dopamine's potential to induce or exacerbate arrhythmias necessitates continuous ECG monitoring throughout the infusion.[11]
• Hypotension After Abrupt Discontinuation: Sudden cessation of the infusion can lead to marked rebound hypotension. The dose must be weaned gradually while expanding blood volume with intravenous fluids.[11]
• Sulfite Hypersensitivity: Pharmaceutical preparations of dopamine contain sodium metabisulfite as a stabilizer. This sulfite can cause severe allergic-type reactions, including anaphylaxis and life-threatening asthmatic episodes, in susceptible individuals. This sensitivity is seen more frequently in people with asthma.[8]

Precautions

• Dopamine should be used with extreme caution in patients with a history of occlusive vascular diseases, such as atherosclerosis, arterial embolism, Raynaud's disease, or diabetic endarteritis, as these individuals are at a heightened risk of developing severe peripheral ischemia and gangrene.[23]
• Metabolic derangements such as hypoxia, hypercapnia, and acidosis should be identified and corrected before or during dopamine administration, as they can reduce the drug's effectiveness and increase the incidence of adverse effects.[9]

Contraindications

There are specific clinical situations in which the use of dopamine is absolutely contraindicated due to an unacceptable risk of severe harm:

• Pheochromocytoma: This is a catecholamine-secreting tumor of the adrenal glands. Administering dopamine, a catecholamine itself, can provoke a massive release of stored catecholamines from the tumor, leading to a life-threatening hypertensive crisis.[12]
• Uncorrected Tachyarrhythmias or Ventricular Fibrillation: Dopamine should not be used in the presence of these dangerous heart rhythms, as its chronotropic and arrhythmogenic properties will exacerbate the condition.[23]

4.3 Significant Drug-Drug Interactions

Dopamine is frequently used in critically ill patients who are often receiving multiple other medications, making a thorough understanding of its drug-drug interactions essential for patient safety. These interactions can significantly potentiate its effects, antagonize its actions, or increase the risk of specific toxicities. A summary of the most critical interactions is provided in Table 3.

Interactions Potentiating Dopamine's Effects

• Monoamine Oxidase Inhibitors (MAOIs): This is the most clinically significant and dangerous interaction. Because dopamine is metabolized by MAO, co-administration with an MAOI blocks its primary degradation pathway. This leads to a dramatic prolongation of its half-life and a potentiation of its effects, which can result in severe hypertension and cardiac arrhythmias. Patients who have been treated with MAOIs within the preceding two to three weeks must receive a substantially reduced initial dose of dopamine, typically no greater than one-tenth (10%) of the usual dose.[12]
• Tricyclic Antidepressants (TCAs): TCAs can potentiate the pressor (blood pressure-raising) response to dopamine, increasing the risk of hypertension.[12]
• Other Vasopressors and Oxytocic Drugs: Concomitant use with other vasoconstricting agents (e.g., norepinephrine, ergonovine) can result in an additive effect, leading to severe and persistent hypertension.[12]

Interactions Antagonizing Dopamine's Effects

• Beta-Adrenergic Blocking Agents: Drugs like propranolol and metoprolol will antagonize the beta-1 mediated cardiac effects of dopamine, reducing its inotropic and chronotropic actions.[23]
• Alpha-Adrenergic Blocking Agents: Drugs like phentolamine antagonize the peripheral vasoconstriction caused by high doses of dopamine. This is the basis for phentolamine's use as an antidote for extravasation.[23]
• Antipsychotic Agents: Dopamine receptor antagonists, such as haloperidol and other butyrophenones or phenothiazines, can block the D1-mediated renal and mesenteric vasodilation produced by low-dose dopamine infusions.[23]

Other Clinically Important Interactions

• Halogenated Hydrocarbon Anesthetics: Anesthetics such as isoflurane, sevoflurane, and desflurane can increase the autonomic irritability of the heart, sensitizing the myocardium to the arrhythmogenic effects of catecholamines like dopamine. Co-administration requires extreme caution and continuous cardiac monitoring due to the increased risk of ventricular arrhythmias and hypertension.[11]
• Phenytoin: The administration of the anticonvulsant phenytoin to patients receiving dopamine has been reported to cause sudden hypotension and bradycardia. Alternative anticonvulsants should be considered if therapy is needed in this setting.[23]

Table 3: Summary of Significant Drug-Drug Interactions with Dopamine

Interacting Drug/Class	Mechanism of Interaction	Clinical Consequence	Management Recommendation	Source(s)
Monoamine Oxidase Inhibitors (MAOIs)	Inhibition of dopamine metabolism	Severe hypertension, cardiac arrhythmias	Reduce initial dopamine dose to ≤10% of usual dose	12
Tricyclic Antidepressants (TCAs)	Potentiation of adrenergic effects	Increased pressor response, hypertension	Monitor blood pressure closely	24
Beta-Blockers	Antagonism at beta-1 adrenoceptors	Decreased cardiac inotropic/chronotropic effects	Monitor for reduced therapeutic effect	24
Alpha-Blockers	Antagonism at alpha-1 adrenoceptors	Antagonism of vasoconstriction	Used as an antidote for extravasation	24
Halogenated Anesthetics	Myocardial sensitization to catecholamines	Increased risk of ventricular arrhythmias, hypertension	Use with extreme caution; monitor ECG continuously	12
Phenytoin	Pharmacodynamic synergism (mechanism unclear)	Hypotension, bradycardia	Avoid concomitant use; consider alternative anticonvulsants	24
Antipsychotics (Dopamine Antagonists)	Antagonism at dopamine receptors	Suppression of renal/mesenteric vasodilation	May negate the effects of low-dose dopamine	24

Section 5: Pharmaceutical and Regulatory Information

This final section addresses the manufacturing and formulation of pharmaceutical-grade dopamine and clarifies its regulatory status. This includes a crucial distinction regarding its labeling in comparison to other drugs that act on the dopamine system.

5.1 Manufacturing and Formulation

Chemical Synthesis

The industrial synthesis of dopamine for pharmaceutical use is designed to produce a high-purity product suitable for intravenous administration. One described manufacturing process involves the demethylation of a precursor molecule. Specifically, 3,4-dimethoxyphenylethylamine hydrochloride is heated with concentrated hydrochloric acid. This process cleaves the two methyl ether groups on the catechol ring, converting them to hydroxyl groups. The resulting product, 3,4-dihydroxyphenylethylamine hydrochloride (dopamine HCl), is then isolated, purified through recrystallization, and prepared as the free base if needed by adding an alkali like sodium hydroxide.5

Pharmaceutical Formulation

For medical use, dopamine is formulated as dopamine hydrochloride. This salt form significantly increases the molecule's stability and enhances its solubility in aqueous solutions, which is essential for creating intravenous preparations.5

• It is supplied as a sterile, pyrogen-free, clear, and practically colorless aqueous solution intended for intravenous infusion.[7]
• It is often provided in pre-diluted solutions, commonly with 5% Dextrose in Water (D5W), at various concentrations (e.g., 800 mcg/mL, 1600 mcg/mL, 3200 mcg/mL) to accommodate different patient needs and fluid restrictions.[23]
• The formulation's pH is adjusted to be acidic (typically between 2.5 and 4.5) to maintain chemical stability. Excipients include an antioxidant, such as sodium metabisulfite, to prevent oxidative degradation, and hydrochloric acid or sodium hydroxide for pH adjustment.[7]
• Common brand names under which dopamine has been marketed include Intropin, Dopastat, and Revivan.[2]

5.2 Regulatory Status and Labeling Insights

Global Status

Reflecting its critical role in managing life-threatening conditions, dopamine is included on the World Health Organization's (WHO) List of Essential Medicines. This designation identifies it as one of the most effective and safe medicines needed in a health system, underscoring its global importance in acute and critical care.10

FDA Labeling and Warnings

The official U.S. Food and Drug Administration (FDA) labeling for intravenous dopamine hydrochloride contains extensive and detailed safety information. The label includes a robust section on "Warnings and Precautions," which highlights the most severe risks associated with its use, such as tissue ischemia from extravasation, cardiac arrhythmias, hypotension following abrupt withdrawal, and hypersensitivity reactions to the sulfite excipient.11

However, it is critically important to note that intravenous dopamine hydrochloride does not carry an FDA "Black Box Warning." A Black Box Warning is the FDA's most stringent warning for drugs and is reserved for products with risks of serious or life-threatening adverse events. The absence of such a warning for dopamine reflects a nuanced regulatory assessment. The risks associated with intravenous dopamine, while severe, are acute, physiological, and immediately observable in a monitored setting (e.g., an arrhythmia appears on an ECG, extravasation is visually apparent). The clinical context of its use—exclusively in high-acuity, continuously monitored environments like an ICU—means that these risks are considered manageable by trained professionals through the existing detailed warnings, precautions, and established treatment protocols.

Distinction from Other Dopaminergic Drugs

This regulatory status stands in stark contrast to other classes of drugs that modulate the dopamine system, and this distinction is vital to prevent clinical confusion.

• Dopamine Agonists: Oral medications used to treat Parkinson's disease and restless leg syndrome (e.g., pramipexole, ropinirole) have been strongly linked to the development of severe and insidious impulse-control disorders, such as pathological gambling, compulsive shopping, and hypersexuality. These adverse effects can develop over time in an outpatient setting and can have devastating psychosocial consequences. Advocacy groups have petitioned the FDA to require Black Box Warnings for this class of drugs due to these risks.[37]
• Dopamine Antagonists: Certain antipsychotic and antiemetic drugs that block dopamine receptors, such as droperidol, have historically carried a Black Box Warning for the risk of serious cardiac events, specifically QT interval prolongation and torsades de pointes.[39]

It must be unequivocally stated that the warnings associated with these other drug classes—particularly the behavioral disorders linked to chronic oral dopamine agonists—do not apply to the short-term, intravenous administration of dopamine as a vasoactive agent in critical care. The different routes of administration, durations of therapy, patient populations, and pharmacological targets result in entirely distinct risk-benefit profiles.

Conclusion

Dopamine is a molecule of remarkable duality, occupying indispensable roles in both foundational neuroscience and high-stakes clinical medicine. Its history charts a direct course from a Nobel Prize-winning discovery that redefined our understanding of brain function to its establishment as a powerful, life-sustaining therapy in the intensive care unit. As a neurotransmitter, it remains a central focus of research into motor control, cognitive function, and the pathophysiology of diseases like Parkinson's and schizophrenia. As a pharmaceutical agent, it is an essential tool for the physiological support of patients in shock.

The cornerstone of its therapeutic utility is its unique, dose-dependent pharmacology. This allows a single agent to be precisely titrated to elicit distinct physiological responses—from enhancing renal perfusion to augmenting cardiac contractility to elevating systemic blood pressure. This versatility makes it an invaluable asset in managing the complex and dynamic nature of hemodynamic collapse.

However, the value of dopamine is inextricably linked to its significant risks. Its potency is matched by a narrow therapeutic index, with the potential to cause severe cardiac arrhythmias, dangerous hypertension, and devastating tissue injury upon extravasation. Its safe and effective application is therefore entirely contingent on a profound clinical understanding of its multifaceted pharmacology and unwavering adherence to strict, evidence-based protocols for administration, titration, and intensive patient monitoring. Ultimately, dopamine exemplifies a class of drugs whose immense benefit in critical illness can only be realized within a framework of expert knowledge, vigilant care, and respect for its inherent dangers.

Works cited

1. Dopamine: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed August 25, 2025, https://go.drugbank.com/drugs/DB00988
2. Dopamine | C8H11NO2 | CID 681 - PubChem, accessed August 25, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Dopamine
3. Dopamine: CAS # 51-61-6 Compound Information and Applications for GC (Gas Chromatography) and LC (Liquid Chromatography) Analysis - EZGC Method Translator, accessed August 25, 2025, https://ez.restek.com/compound/view/en/51-61-6/Dopamine
4. Dopamine | CAS 51-61-6 | SCBT - Santa Cruz Biotechnology, accessed August 25, 2025, https://www.scbt.com/p/dopamine-51-61-6
5. 51-61-6 | CAS DataBase - ChemicalBook, accessed August 25, 2025, https://m.chemicalbook.com/CASEN_51-61-6.htm
6. Dopamine (DA, 3-hydroxy Tyramine, KW 3160, NSC 173182, CAS Number: 51-61-6), accessed August 25, 2025, https://www.caymanchem.com/product/36532/dopamine
7. DOPamine HYDROCHLORIDE AND 5% DEXTROSE INJECTION, USP - accessdata.fda.gov, accessed August 25, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/018132s067,018826s045lbl.pdf
8. Label: DOPAMINE HYDROCHLORIDE injection - DailyMed, accessed August 25, 2025, https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c901b461-4f98-da0a-e053-2a95a90a106e
9. DOPAMINE HCI INJ., USP 400mg (40mg/mL) 10mL VIAL - DailyMed, accessed August 25, 2025, https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=74205252-3949-57fa-e053-2991aa0aee4d
10. Dopamine - Wikipedia, accessed August 25, 2025, https://en.wikipedia.org/wiki/Dopamine
11. DOPAMINE HYDROCHLORIDE INJECTION - accessdata.fda.gov, accessed August 25, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/018132Orig1s071lbl.pdf
12. Dopamine Hydrochloride in Dextrose Injection - This label may not be the latest approved by FDA. For current labeling information, please visit https://www.fda.gov/drugsatfda, accessed August 25, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/018826s047lbl.pdf
13. The Discovery of Dopamine - Lund University Neuroscience, accessed August 25, 2025, https://www.neuroscience.lu.se/sites/neuroscience.lu.se/files/the_discovery_of_dopamine_pdf.pdf
14. Arvid Carlsson, and the story of dopamine - PMC, accessed August 25, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC2824994/
15. Dopamine: What It Is, Function & Symptoms - Cleveland Clinic, accessed August 25, 2025, https://my.clevelandclinic.org/health/articles/22581-dopamine
16. What is Dopamine? - News-Medical, accessed August 25, 2025, https://www.news-medical.net/health/What-is-Dopamine.aspx
17. The Role of Dopamine and Its Dysfunction as a Consequence of Oxidative Stress - PMC, accessed August 25, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4684895/
18. www.ncbi.nlm.nih.gov, accessed August 25, 2025, https://www.ncbi.nlm.nih.gov/books/NBK536726/figure/Ch7-f0001/#:~:text=Dopamine%20is%20synthesized%20from%20phenylalanine,a%20minor%20pathway%20by%20CYP2D6.
19. Dopamine - StatPearls - NCBI Bookshelf, accessed August 25, 2025, https://www.ncbi.nlm.nih.gov/books/NBK535451/
20. Dopamine - StatPearls - NCBI Bookshelf, accessed August 25, 2025, https://www.ncbi.nlm.nih.gov/sites/books/NBK535451/
21. Figure 1, [Metabolic pathway of dopamine synthesis...]. - Parkinson's Disease - NCBI Bookshelf, accessed August 25, 2025, https://www.ncbi.nlm.nih.gov/books/NBK536726/figure/Ch7-f0001/
22. Dopamine- mechanisms of action - Australian Prescriber, accessed August 25, 2025, https://australianprescriber.tg.org.au/articles/dopamine-mechanisms-of-action.html
23. DOPamine Hydrochloride and 5% Dextrose ... - accessdata.fda.gov, accessed August 25, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/019615s024lbl.pdf
24. Side Effects of Dopamine Injection: Interactions & Warnings, accessed August 25, 2025, https://www.medicinenet.com/side_effects_of_dopamine-injection/side-effects.htm
25. Dopamine Pharmacodynamics: New Insights - PMC - PubMed Central, accessed August 25, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11121567/
26. DOPAMINE (Intropin) | LHSC, accessed August 25, 2025, https://www.lhsc.on.ca/critical-care-trauma-centre/dopamine-intropin
27. Dopamine | Davis's Drug Guide for Rehabilitation Professionals ..., accessed August 25, 2025, https://fadavispt.mhmedical.com/content.aspx?bookid=1873§ionid=139009013
28. Dopamine - Mechanism, Indication, Contraindications, Dosing, Adverse Effect, Interaction, Renal Dose, Hepatic Dose | Drug Index | Pediatric Oncall, accessed August 25, 2025, https://www.pediatriconcall.com/drugs/dopamine/512
29. Dopamine Injection: Treatment & Side Effects - Cleveland Clinic, accessed August 25, 2025, https://my.clevelandclinic.org/health/drugs/20872-dopamine-injection
30. Dopamine - Side Effects, Dosage, Precautions, Uses - Yashoda Hospital, accessed August 25, 2025, https://www.yashodahospitals.com/medicine-faqs/dopamine/
31. dopamine hydrochloride injection, USP VIAL Warnings and Precautions | Pfizer Medical, accessed August 25, 2025, https://www.pfizermedical.com/dopamine/warnings
32. 19615S012 Dopamine HCl and 5 Percent Dextroxse Injection Approval - accessdata.fda.gov, accessed August 25, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/19615S012_Dopamine.pdf
33. What are the side effects of Dopamine hydrochloride? - Patsnap Synapse, accessed August 25, 2025, https://synapse.patsnap.com/article/what-are-the-side-effects-of-dopamine-hydrochloride
34. Dopamine Side Effects: Common, Severe, Long Term - Drugs.com, accessed August 25, 2025, https://www.drugs.com/sfx/dopamine-side-effects.html
35. www.medicinenet.com, accessed August 25, 2025, https://www.medicinenet.com/side_effects_of_dopamine-injection/side-effects.htm#:~:text=Drug%20interactions%20of%20dopamine%20include,abnormal%20heart%20rate%20and%20rhythm.
36. Intropin (dopamine) dosing, indications, interactions, adverse effects, and more, accessed August 25, 2025, https://reference.medscape.com/drug/intropin-dopamine-342435
37. Public Citizen demands 'black box' warnings on gambling, sex urges for dopamine meds, accessed August 25, 2025, https://www.fiercepharma.com/pharma/public-citizen-petitions-fda-for-stronger-warnings-gambling-sex-urges-for-dopamine-meds
38. Petition to the FDA to Require a Black-Box Warning for Dopamine Agonist Drugs, accessed August 25, 2025, https://www.citizen.org/article/petition-to-the-fda-to-require-a-black-box-warning-for-dopamine-agonist-drugs/
39. Evidence-based review and appraisal of the use of droperidol in the emergency department, accessed August 25, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5883829/